Enzyme News and Research

RSS

Two high blood pressure medicines effective in treating stable ischemic heart disease

Two medications commonly used to treat high blood pressure appear to be effective in treating a common type of heart disease known as stable ischemic heart disease, according to a new comparative effectiveness review funded by HHS' Agency for Healthcare Research and Quality.

20 Oct 2009

New technique to treat metabolic disorders in babies while still in the womb

Researchers say a new development in cord blood transplants for inherited metabolic disorders may be curative for some babies who are treated while still in the womb.

20 Oct 2009

Alnara Pharmaceuticals’ announces results of its international Phase 3 study of liprotamase

Alnara Pharmaceuticals, a pharmaceutical company developing novel, non-systemic orally delivered protein therapeutics for the treatment of metabolic diseases, today announced results from an international, Phase 3 open-label, long-term safety study demonstrating the safety and nutritional benefits of liprotamase, a novel pancreatic enzyme replacement therapy (PERT) for patients with cystic fibrosis (CF).

19 Oct 2009

Boehringer Ingelheim Pharmaceuticals receives NDA approval from FDA for its Micardis Tablets 80 mg

Boehringer Ingelheim Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) approved the supplemental New Drug Application (sNDA) for its angiotensin II receptor blocker (ARB) Micardis® (telmisartan) Tablets 80 mg for reduction of the risk of myocardial infarction, stroke, or death from cardiovascular causes in patients 55 years of age or older at high risk of developing major cardiovascular events who are unable to take angiotensin-converting enzyme (ACE) inhibitors.(1) MICARDIS is the most studied ARB in this high-risk patient population and has been commercially available to treat hypertension (high blood pressure) since its approval in 1998.

19 Oct 2009

UCSC professors receive $1.8M grant under NHGRI's genome sequencing technology development programme

Oxford Nanopore Technologies congratulates our collaborators Professor Mark Akeson and Professor David Deamer of the University of California, Santa Cruz (UCSC) on receiving a grant of $1.1 million, and Professor Jene Golovchenko of the University of Harvard on receiving $745,000 following on from a previous grant of $6.5 million.

From Oxford Nanopore Technologies 19 Oct 2009

New chromosomal abnormality in acute lymphoblastic leukemia

Researchers identified a new chromosomal abnormality in acute lymphoblastic leukemia (ALL) that appears to work in concert with another mutation to give rise to cancer. This latest anomaly is particularly common in children with Down syndrome.

19 Oct 2009

DKC establishes link between genetic mutation affecting telomerase function and human disease

The human genetic disease dyskeratosis congenita (DKC) is an autosomal dominant disease that leads to abnormalities in tissues with a rapid cell turnover - the skin, nails, bone marrow, lungs and gut. Patients with DKC experience life-threatening symptoms. Bone marrow failure increases their risk of fatal infections and cancer. Many die before the age of 30 and management of the disease is limited to trying to treat its symptoms.

19 Oct 2009

APP balance critical for normal neuronal development

New data about amyloid precursor protein, or APP, a protein implicated in development of Alzheimer's disease, suggests it also may have a positive role -- directly affecting learning and memory during brain development. So is APP good or bad? Researchers at Georgetown University Medical Center say both, and that a balance of APP is critical.

19 Oct 2009

Enzo Biochem to release a new catalog dealing with epigenetics and chromatin modification

Enzo Biochem, Inc. today said that its Life Sciences subsidiary will release a new catalog dealing with “Epigenetics & Chromatin Modification” at the Society for Neuroscience’s, Neuroscience 2009 conference, beginning October 17, 2009, in Chicago, Illinois.

15 Oct 2009

Baxter International announces financial results for third quarter 2009; updates full-year financial outlook

Baxter International Inc. today reported solid financial results for the third quarter of 2009, and provided its fourth quarter and updated full-year 2009 financial outlook.

From Baxter International Inc. 15 Oct 2009

Patients on statin drugs may have lower AAA surgery costs

Patients taking cholesterol-lowering statin drugs may have better results and lower procedure costs when having a common operation for repairing a bulging aorta, according to a new study presented at the 95th annual Clinical Congress of the American College of Surgeons.

15 Oct 2009

Curemark commences enrollment in Phase III CM-AT clinical trials for autism treatment

Curemark, LLC, a drug research and development company focused on the treatment of neurological diseases, announced that it has enrolled the first patients in Phase III clinical trials for its autism treatment, CM-AT. The first clinical trial patients have been enrolled at Lake Mary Pediatrics in Orange City, Florida, one of 12 clinical trial sites with a total 170 children across the country.

15 Oct 2009

Affymetrix unveils Axiom Genotyping Solution

Affymetrix, Inc. (Nasdaq:AFFX) today announced the launch of the Axiom Genotyping Solution, its next-generation array technology designed to match the significant rise in genetic content generated by government and privately funded sequencing projects.

From Beckman Coulter Life Sciences - Automation and Genomics 15 Oct 2009

FDA approves ZyStor Therapeutics' ZC-701 for Phase I human safety trial

ZyStor Therapeutics, Inc., a biotechnology company developing a new class of targeted protein therapeutics for the treatment of Lysosomal Storage Diseases using the Company's proprietary Glycosylation Independent Lysosomal Targeting technology, today announced that it has received clearance from the U. S. Food and Drug Administration to proceed into a clinical trial for its first drug candidate, ZC-701, an enzyme replacement therapy for the treatment of Pompe disease.

14 Oct 2009

Global Bioenergies discovers synthetic metabolic pathway for producing isobutene

Global Bioenergies, located on the Genopole campus close to Paris, has today announced the proof-of-concept of a synthetic metabolic pathway for producing isobutene, a key building block that can be converted into transportation fuels, polymers and various commodity chemicals.

14 Oct 2009

NYU-Poly scientists develop a new method of protein stabilization

Scientists at the Polytechnic Institute of New York University report they have developed a novel method of stabilizing proteins, including important enzymes used to produce certain artificial sweeteners and bio-ethanol.

14 Oct 2009

Researchers discover compounds that show promise as novel treatments for AIDS

While studying an HIV protein that plays an essential role in AIDS progression, researchers at the University of Pittsburgh School of Medicine have discovered compounds that show promise as novel treatments for the disease.

14 Oct 2009

SCID infants who receive early bone marrow transplants are likely to have fewer complications

Mention the words "bubble boy" and many will recall David Vetter, the kid with big eyes and a thick thatch of dark hair who died 25 years ago after spending almost the entire 12 years of his life in a germ-free, plastic bubble. David was born with severe combined immune deficiency, or SCID, a condition that robbed him of an immune system.

14 Oct 2009

Research reveals the genetic basis of DispersinB enzyme substrate based biofilm formation in bacteria

Kane Biotech Inc., a biotechnology company engaged in the development of products that prevent and disperse bacterial biofilms is pleased to announce that a recent research publication from Princeton University reveals the genetic basis of poly-ß-1,6-N-acetylglucosamine (PNAG), the DispersinB® enzyme substrate, based biofilm formation in bacteria.

14 Oct 2009

Researchers test Orizon Research's ALKA-V6 silicon-based compound

Researchers at Texas State University-San Marcos have completed initial testing of a cancer chemotherapeutic and anti-retroviral compound with promising results.

14 Oct 2009

Enzyme News and Research

Two high blood pressure medicines effective in treating stable ischemic heart disease

New technique to treat metabolic disorders in babies while still in the womb

Alnara Pharmaceuticals’ announces results of its international Phase 3 study of liprotamase

Boehringer Ingelheim Pharmaceuticals receives NDA approval from FDA for its Micardis Tablets 80 mg

UCSC professors receive $1.8M grant under NHGRI's genome sequencing technology development programme

New chromosomal abnormality in acute lymphoblastic leukemia

DKC establishes link between genetic mutation affecting telomerase function and human disease

APP balance critical for normal neuronal development

Enzo Biochem to release a new catalog dealing with epigenetics and chromatin modification

Baxter International announces financial results for third quarter 2009; updates full-year financial outlook

Patients on statin drugs may have lower AAA surgery costs

Curemark commences enrollment in Phase III CM-AT clinical trials for autism treatment

Affymetrix unveils Axiom Genotyping Solution

FDA approves ZyStor Therapeutics' ZC-701 for Phase I human safety trial

Global Bioenergies discovers synthetic metabolic pathway for producing isobutene

NYU-Poly scientists develop a new method of protein stabilization

Researchers discover compounds that show promise as novel treatments for AIDS

SCID infants who receive early bone marrow transplants are likely to have fewer complications

Research reveals the genetic basis of DispersinB enzyme substrate based biofilm formation in bacteria

Researchers test Orizon Research's ALKA-V6 silicon-based compound

Biochemical Assays for Efficient Hit Prioritization After Screening eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo